Get the Stockscreener App
220.38
1.96%
-4.0848
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $220.38, with a volume of 729.68K.
It is down -1.96% in the last 24 hours and up +10.59% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$224.46
Open:
$222.68
24h Volume:
729.68K
Relative Volume:
0.49
Market Cap:
$31.83B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
21.24
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+0.01%
1M Performance:
+10.59%
6M Performance:
-13.98%
1Y Performance:
-22.76%
1-Day Range:
$218.66
$223.94
1-Week Range:
$215.71
$228.55
52-Week Range:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
220.66 | 32.38B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
390.88 | 139.37B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
182.26 | 49.96B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
72.61 | 35.89B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.70 | 31.36B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Could Cochlear (ASX:COH) and ResMed (ASX:RMD) Shape the Next Chapter? - Kalkine Media
87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co - MarketBeat
41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V. - MarketBeat
Why You Should Consider Buying ResMed Stock After Its First-Ever Annual Guide - TIKR.com
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call - Yahoo Finance
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed Inc.: Financial Data Forecasts Estimates and Expectations | RMEA | AU000000RMD6 - marketscreener.com
ResMed, Inc.: Financial Data Forecasts Estimates and Expectations | RME | US7611521078 - marketscreener.com
ResMed (ASX:RMD) Keeps Dividend Momentum Going: Keep It on Your Radar - Kalkine
ResMed to sell MatrixCare business for $490 million - Minichart
ResMed Inc. Submits Annual 10-K Report for Fiscal Year Ending June 30, 2026 - Kalkine Media
ResMed Inc. Files Annual Form 10-K Report for Fiscal Year Ended June 30, 2026 - Kalkine
ResMed Submits 2026 Fiscal Year-End 10-K Annual Report Detailing Financial and Operational Metrics - Kalkine Media
RESMED INC. : RBC RAISES TARGET PRICE TO $244 FROM $234 - webull.com
RESMED INC FY 2026: Revenue $5.65B, EPS $10.43— 10-K Summary - TradingView
How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds - simplywall.st
Handelsbanken Fonder AB Raises Stock Position in ResMed Inc. $RMD - MarketBeat
Weekly Earnings Wrap: CBA, REA Group, Westpac, Resmed and more - Morningstar Australia
ResMed Inc. Stock 12‑Month Price Target Cut to $258.47, Implies 14% Upside - TradingView
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook - Yahoo Finance
ASX healthcare share remains cheap despite mixed earnings result - Morningstar Australia
Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)? - Yahoo Finance
ResMed Chairman and CEO Michael Farrell Sells 4,991 Shares Under 10b5-1 Plan - Kalkine
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
ResMed CEO Michael Farrell sells $1.03m in company stock By Investing.com - Investing.com India
Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,026,598.79 in Stock - MarketBeat
ResMed CEO Michael Farrell sells $1.03m in company stock - Investing.com
Resmed Insider Sold Shares Worth $1,026,596, According to a Recent SEC Filing - marketscreener.com
Assenagon Asset Management S.A. Grows Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Bull Thinks Five-Year Outlook Is Intact -- Market Talk - Moomoo
Ord Minnett Remains a Buy on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Macquarie Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Citi Sticks to Their Hold Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Is It Too Late to Buy ResMed Inc (RMD) After 3.8% Rally? GF Value Says Undervalued - GuruFocus
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed’s Margin Squeeze and Astral Recall Overshadow Product Rollout and $1.5 Billion Buyback Plan - finance.biggo.com
Operating margin % of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAM:RMEA - TradingView
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh - TradingView
Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled - TradingKey
Resmed’s stock falls by 7% on soft FY27 outlook - Medical Device Network
ResMed Inc. (RMD) Stock Analysis: Unveiling a 16.64% Potential Upside in the Healthcare Sector - directorstalkinterviews.com
ResMed: Result 2026 - intelligentinvestor.com.au
ResMed Price Target Raised 0.4% to A$46.80/Share by Macquarie - Moomoo
ResMed Inc. (NYSE:RMD) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - 富途牛牛
Here's What Analysts Are Forecasting For ResMed Inc. (NYSE:RMD) After Its Full-Year Results - simplywall.st
ResMed Q4 Earnings Call Highlights - Yahoo Finance
RESMED INC. (RMEA.SG) Q3 FY2026 earnings call transcript - Yahoo Finance
RESMED INC. : WELLS FARGO CUTS TARGET PRICE TO $215 FROM $225 - webull.com
ResMed Is Maintained at Sector Perform by RBC Capital - Moomoo
ResMed Price Target Raised to $244.00/Share From $234.00 by RBC Capital - Moomoo
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):